Health TrialsbyHealthPanel

Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa

ConditionHidradenitis Suppurativa (HS)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-75
SponsorGeisinger Clinic

About this trial

The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)

12-75 years of age

Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)

Must have not used systemic therapies within 2 weeks of enrollment in study

Disqualifiers

Patients who cannot tolerate laser therapy

Patients who cannot wear protective eyewear

Patients who are pregnant

Trial design

Design model

Single group

Treatments tested in this trial

  • Nd:YAG Laser

    Device

    Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

  • Alexandrite Laser

    Device

    Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

Treatment groups

21 Participants
are divided into 1 treatment group
Group A: Receiving treatment with both laser typesExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

HiSCR50

Percentage of patients achieving a 50% reduction in their hidradenitis suppurativa clinical response (HiSCR) score.

Time frame
6 months
2

HiSQOL

The Hidradenitis Suppurativa Quality Of Life (HiSQOL) scale, a validated HS quality of life index and is comprised of a 17-item HS-specific HRQOL instrument with a 7-day recall period. Score ranges from 0 to 68, with higher scores indicating more severe impact

Time frame
6 months

Secondary outcomes

1

Pain VAS score

Visual analogue score for pain ranging from 0-10 with higher scores indicating worse pain.

Time frame
6 months
2

Pruritus numeric rating scale

As measured by a numeric rating scale from 0-10 with higher scores indicating worse itching.

Time frame
6 months
3

Days free of disease in last 30 days

The number of days a patient has not had a flare of HS in the past 30 days.

Time frame
6 months
4

AN Count

Number of abscesses and nodules on exam

Time frame
6 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Geisinger Clinic

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: